Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin M Murray

Showing results (21-30 of 593) with videos related to

Pageof 60
Sort By:
BMJ (Clinical Research Ed.)|January 22, 2013
Can we identify and treat "schizophrenia light" to prevent true psychotic illness?Jim van Os, Robin M Murray
Dialogues in Clinical Neuroscience|November 9, 2020
Cannabis points to the synaptic pathology of mental disorders: how aberrant synaptic components disrupt the highest psychological functions
Paul D Morrison, Robin M Murray
Therapeutic Advances in Psychopharmacology|April 3, 2018
The antipsychotic landscape: dopamine and beyondPaul D Morrison, Robin M Murray
Biological Psychiatry|March 13, 2016
Cannabis and Psychosis: What Degree of Proof Do We Require?Robin M Murray, Marta Di Forti
BMJ (Clinical Research Ed.)|July 14, 2007
SchizophreniaMarco M Picchioni, Robin M Murray
Dialogues in Clinical Neuroscience|October 20, 2010
The epidemiology of schizophrenia: replacing dogma with knowledgeSimona A Stilo, Robin M Murray
Current Psychiatry Reports|September 16, 2019
Non-Genetic Factors in SchizophreniaSimona A Stilo, Robin M Murray
International Clinical Psychopharmacology|February 7, 2003
Schizophrenia and bipolar disorder: similarities in pathogenic mechanisms but differences in neurodevelopmentJenny Walker, Vivienne Curtis, Robin M Murray
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|September 2, 2006
Neurodevelopmental impairment, dopamine sensitisation, and social adversity in schizophreniaRobin M Murray, Colm McDonald, Elvira Bramon
Journal of Psychiatric Practice|June 30, 2005
The causes of schizophrenia: neurodevelopment and other risk factorsKimberlie Dean, Elvira Bramon, Robin M Murray
Pageof 60

Showing results (21-30 of 593) with videos related to

Sort By:
Pageof 60
BMJ (Clinical Research Ed.)|January 22, 2013
Can we identify and treat "schizophrenia light" to prevent true psychotic illness?Jim van Os, Robin M Murray
Dialogues in Clinical Neuroscience|November 9, 2020
Cannabis points to the synaptic pathology of mental disorders: how aberrant synaptic components disrupt the highest psychological functions
Paul D Morrison, Robin M Murray
Therapeutic Advances in Psychopharmacology|April 3, 2018
The antipsychotic landscape: dopamine and beyondPaul D Morrison, Robin M Murray
Biological Psychiatry|March 13, 2016
Cannabis and Psychosis: What Degree of Proof Do We Require?Robin M Murray, Marta Di Forti
BMJ (Clinical Research Ed.)|July 14, 2007
SchizophreniaMarco M Picchioni, Robin M Murray
Dialogues in Clinical Neuroscience|October 20, 2010
The epidemiology of schizophrenia: replacing dogma with knowledgeSimona A Stilo, Robin M Murray
Current Psychiatry Reports|September 16, 2019
Non-Genetic Factors in SchizophreniaSimona A Stilo, Robin M Murray
International Clinical Psychopharmacology|February 7, 2003
Schizophrenia and bipolar disorder: similarities in pathogenic mechanisms but differences in neurodevelopmentJenny Walker, Vivienne Curtis, Robin M Murray
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|September 2, 2006
Neurodevelopmental impairment, dopamine sensitisation, and social adversity in schizophreniaRobin M Murray, Colm McDonald, Elvira Bramon
Journal of Psychiatric Practice|June 30, 2005
The causes of schizophrenia: neurodevelopment and other risk factorsKimberlie Dean, Elvira Bramon, Robin M Murray
Pageof 60